Abstract
The rate of asymptomatic amyloidosis (AL) among patients with newly diagnosed multiple myeloma (MM) or smoldering multiple myeloma (SMM) is unknown. We evaluated number and clinical significance of asymptomatic AL in consecutive MM and SMM patients, not having recognition of symptomatic AL at the time of their diagnostic bone marrow biopsy. Bone marrow biopsies were stained with Congo red and considered diagnostic for AL in case of positive Congo red staining with apple-green birefringence. Biopsies from 144 patients were evaluated: 77 had a diagnosis of MM and 67 of SMM. The median age was 59 (range 26–84) years; the median follow-up was 76 months (range 0–216). Immunoglobulin isotypes were 96/144 (67%), IgG; 23/144 (16%), IgA; 12/144 (8%), light chain only; 1/77 (1%), IgD; and biclonal or indeterminate, 12/144 (8%). Fifty-eight percent (84/144) were κ restricted. The presence of amyloid was found in two cases (1%, 95% CI −0.6 to 3.2), one in MM, and one in SMM group, and none had or developed signs or symptoms suggestive of organ involvement by amyloid. Among the 142 other patients without amyloid deposition in their index bone marrow, one (0.7%, 95% CI −0.6 to 2.0) developed symptomatic AL after 119 months.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gertz MA, Lacy MQ, Dispenzieri A (1999) Amyloidosis. Hematol Oncol Clin North Am 13:1211–1233
Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32:45–59
Rajkumar SV, Dispenzieri A, Kyle RA (2006) Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 81(5):693–703
Rajkumar SV, Gertz MA, Kyle RA (1998) Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 82:1501–1505
Kyle RA (1995) Multiple myeloma and other plasma cell disorders. In: Hoffman R, Benz EJ, Shattil SJ, Cohen FB, LE HJ S (eds) Hematology, basic principles and practice, 2nd edn. Churchill Livingstone, New York, pp 1354–1374
Desikan KR, Dhodapkar MV, Hough A et al (1997) Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 27:315–319
Bahlis NJ, Lazarus HM (2006) Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? Bone Marrow Transplant 38(1):7–15
Vela-Ojeda J, García-Ruiz Esparza MA, Padilla-González Y et al (2009) Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. Ann Hematol 88(1):59–66
The UK Myeloma Forum AL Amyloidosis Guidelines Working Group (2004) Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 125:681–700
Kyle RA, Remstein ED, Therneau TM et al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25):2582–2590
Duston MA, Skinner M, Shraham T et al (1987) Diagnosis of amyloidosis by abdominal fat aspiration: analysis of 4 years experience. Am J Med 82:412–414
Petruzziello F, Zeppa P, Catalano L et al (2010) Amyloid in bone marrow smears of patients affected by multiple myeloma. Ann Hematol 89(5):469–474
Solomon A, Weiss DT, Kattine AA et al (1991) Nephrotoxic potential of Bence Jones proteins. N Engl J Med 324(26):1845–1851
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Siragusa, S., Morice, W., Gertz, M.A. et al. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol 90, 101–106 (2011). https://doi.org/10.1007/s00277-010-1028-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-010-1028-8